Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Medtronic
Harvard Business School
Baxter
Dow

Last Updated: May 19, 2022

MOVIPREP Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Moviprep patents expire, and what generic alternatives are available?

Moviprep is a drug marketed by Salix Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-four patent family members in twenty-two countries.

The generic ingredient in MOVIPREP is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Moviprep

Annual sales in 2019 were $1mm indicating the motivation for generic entry (peak sales were $33mm in 2009).

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for MOVIPREP
Drug patent expirations by year for MOVIPREP
Drug Prices for MOVIPREP

See drug prices for MOVIPREP

Drug Sales Revenue Trends for MOVIPREP

See drug sales revenues for MOVIPREP

Paragraph IV (Patent) Challenges for MOVIPREP
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MOVIPREP For Oral Solution ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate 100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch 021881 1 2007-11-27

US Patents and Regulatory Information for MOVIPREP

MOVIPREP is protected by two US patents.

Patents protecting MOVIPREP

Colon cleansing compositions and methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Colon cleansing compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms MOVIPREP ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 021881-001 Aug 2, 2006 AA RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Salix Pharms MOVIPREP ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 021881-001 Aug 2, 2006 AA RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for MOVIPREP

When does loss-of-exclusivity occur for MOVIPREP?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 03274377
Estimated Expiration: See Plans and Pricing

Patent: 08100865
Estimated Expiration: See Plans and Pricing

Patent: 09227838
Estimated Expiration: See Plans and Pricing

Austria

Patent: 4223
Estimated Expiration: See Plans and Pricing

Canada

Patent: 02103
Estimated Expiration: See Plans and Pricing

Patent: 72427
Estimated Expiration: See Plans and Pricing

China

Patent: 05494
Estimated Expiration: See Plans and Pricing

Patent: 1897721
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 08505
Estimated Expiration: See Plans and Pricing

Patent: 13933
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 67193
Estimated Expiration: See Plans and Pricing

Patent: 14304
Estimated Expiration: See Plans and Pricing

Patent: 14319
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 67193
Estimated Expiration: See Plans and Pricing

Patent: 14304
Estimated Expiration: See Plans and Pricing

Patent: 14319
Estimated Expiration: See Plans and Pricing

Germany

Patent: 758361
Estimated Expiration: See Plans and Pricing

Patent: 014286
Estimated Expiration: See Plans and Pricing

Patent: 321510
Estimated Expiration: See Plans and Pricing

Patent: 322940
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 77196
Estimated Expiration: See Plans and Pricing

Patent: 26678
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 45881
Estimated Expiration: See Plans and Pricing

Japan

Patent: 31266
Estimated Expiration: See Plans and Pricing

Patent: 84770
Estimated Expiration: See Plans and Pricing

Patent: 60320
Estimated Expiration: See Plans and Pricing

Patent: 06507281
Estimated Expiration: See Plans and Pricing

Patent: 08001724
Estimated Expiration: See Plans and Pricing

Patent: 12025732
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 14319
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 05004347
Estimated Expiration: See Plans and Pricing

Poland

Patent: 6059
Estimated Expiration: See Plans and Pricing

Patent: 0812
Estimated Expiration: See Plans and Pricing

Patent: 4822
Estimated Expiration: See Plans and Pricing

Patent: 3711
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 67193
Estimated Expiration: See Plans and Pricing

Patent: 14304
Estimated Expiration: See Plans and Pricing

Patent: 14319
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 53412
Estimated Expiration: See Plans and Pricing

Patent: 19562
Estimated Expiration: See Plans and Pricing

Patent: 00790
Estimated Expiration: See Plans and Pricing

Patent: 05116023
Estimated Expiration: See Plans and Pricing

Patent: 09105770
Estimated Expiration: See Plans and Pricing

Patent: 11144613
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 67193
Estimated Expiration: See Plans and Pricing

Patent: 14304
Estimated Expiration: See Plans and Pricing

Patent: 14319
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0503247
Estimated Expiration: See Plans and Pricing

Spain

Patent: 85970
Estimated Expiration: See Plans and Pricing

Patent: 19093
Estimated Expiration: See Plans and Pricing

Patent: 39387
Estimated Expiration: See Plans and Pricing

Turkey

Patent: 1909741
Estimated Expiration: See Plans and Pricing

United Kingdom

Patent: 24909
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MOVIPREP around the world.

Country Patent Number Title Estimated Expiration
Poland 374822 Kompozycje do oczyszczania okrężnicy (COLON CLEANSING COMPOSITIONS) See Plans and Pricing
Cyprus 1113933 See Plans and Pricing
Russian Federation 2353412 СУХАЯ КОМПОЗИЦИЯ ДЛЯ СМЕШИВАНИЯ С ВОДОЙ, ОЧИСТИТЕЛЬНЫЙ ПРЕПАРАТ (ВАРИАНТЫ), НАБОР КОМПОНЕНТОВ ДЛЯ ОЧИСТКИ ТОЛСТОЙ КИШКИ (ВАРИАНТЫ), ПОЛИЭТИЛЕНГЛИКОЛЬ В КАЧЕСТВЕ СРЕДСТВА ДЛЯ ОЧИСТКИ ТОЛСТОЙ КИШКИ (ВАРИАНТЫ) И СПОСОБ ОЧИЩЕНИЯ ТОЛСТОЙ КИШКИ (ВАРИАНТЫ) (POWDER/WATER MIXTURE, CLEANING AGENT (VERSIONS), COMPONENT SET FOR LARGE INTESTINE DEPLETION (VERSIONS), POLYETHYLENE GLYCOL AS LARGE INTESTINE DEPLETION AGENT (VERSIONS) AND METHOD OF LARGE INTESTINE DEPLETION (VERSIONS)) See Plans and Pricing
China 1705494 Colon cleansing compositions and methods See Plans and Pricing
Japan 2006507281 See Plans and Pricing
European Patent Office 1567193 COMPOSITIONS DE NETTOYAGE DU COLON (COLON CLEANSING COMPOSITIONS) See Plans and Pricing
United Kingdom 0224909 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MOVIPREP

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3141251 C202130017 Spain See Plans and Pricing PRODUCT NAME: COMBINACION DE PRINCIPIOS ACTIVOS EN DOS DOSIS, EN LA QUE LA PRIMERA DOSIS CONSISTE EN LOS PRINCIPIOS ACTIVOS POLIETILENGLICOL, SULFATO DE SODIO, CLORURO DE SODIO Y CLORURO DE POTASIO, Y LA SEGUNDA DOSIS CONSISTE EN LOS PRINCIPIOS ACTIVOS POLIETILENGLICOL, ACIDO ASCORBICO, ASCORBATO DE SODIO, CLORURO DE SODIO Y CLORURO DE POTASIO.; NATIONAL AUTHORISATION NUMBER: 82959-SE/H/1801/001/DC; DATE OF AUTHORISATION: 20180525; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): IS/1/17/083/01; DATE OF FIRST AUTHORISATION IN EEA: 20171016
3141251 301099 Netherlands See Plans and Pricing PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
3141251 132021000000044 Italy See Plans and Pricing PRODUCT NAME: UN PRODOTTO MEDICINALE COSTITUITO DA UNA COMBINAZIONE DI UNA PRIMA DOSE DI COMPOSIZIONE FARMACEUTICA E UNA SECONDA DOSE DI COMPOSIZIONE FARMACEUTICA, LA PRIMA DOSE DI COMPOSIZIONE FARMACEUTICA E COSTITUITA DAGLI INGREDIENTI ATTIVI POLIETILENGLICOLE, SOLFATO DI SODIO, CLORURO DI SODIO E CLORURO DI POTASSIO E LA SECONDA DOSE DI COMPOSIZIONE FARMACEUTICA E COSTITUITA DAGLI INGREDIENTI ATTIVI POLIETILENGLICOLE, ACIDO ASCORBICO, ASCORBATO DI SODIO, CLORURO DI SODIO E CLORURO DI POTASSIO.(PLENVU); AUTHORISATION NUMBER(S) AND DATE(S): IS/1/17/083/01, 20171016;045671017, 045671029, 045671031, 045671043, 045671056, 20171213
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKinsey
Moodys
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.